FDA calls out Sanofi emails for giving 'misleading impression' of Beyfortus use in RSV

The FDA has called out Sanofi’s promotion of respiratory syncytial virus (RSV) antibody Beyfortus in a new untitled letter, taking issue with the company’s characterization of the med as a general | The FDA's Office of Prescription Drug Promotion took issue with Sanofi's characterization of antibody Beyfortus as an RSV preventative, as the med is specifically indicated for RSV lower respiratory tract disease.